What is Organon's vtama — revenue?

Organon (OGN) reported vtama — revenue of $25M in Q1 2026.

How has Organon's vtama — revenue changed year-over-year?

Organon's vtama — revenue increased by 4.2% year-over-year, from $24M to $25M.

What does vtama — revenue mean?

This metric represents the total gross sales generated from the specific pharmaceutical product or therapeutic line. It serves as a primary indicator of market adoption, commercial success, and the revenue-generating capacity of the asset within the company's portfolio.

Organon OGN Vtama — Revenue

Other product segments

Nexplanon/Implanon NXT

$201M-19.0%

Other

$87M+11.5%

Zetia

$87M+2.4%

Atozet

$85M+10.4%

Other Non-Opiod Pain, Bone and Dermatology

$68M0.0%

Hadlima

$67M+42.6%

Nasonex

$65M-9.7%

Follistim AQ

$61M-11.6%

Arcoxia

$59M-4.8%

Cozaar/Hyzaar

$57M+3.6%

Renflexis

$57M0.0%

Emgality

$54M+68.8%

Other Women's Health

$46M+7.0%

Singulair

$40M-45.9%

Diprospan

$35M+16.7%

Dulera

$35M-18.6%

Clarinex

$31M-8.8%

Propecia

$30M+15.4%

Fosamax

$29M-12.1%

Other Cardiovascular

$28M-6.7%

Ganirelix Acetate Injection

$26M-3.7%

Marvelon/Mercilon

$26M-33.3%

Proscar

$26M+8.3%

NuvaRing

$24M+9.1%

Other Biosimilars

$24M—

Vytorin

$21M-8.7%

Brenzys

$20M+42.9%

Other Respiratory

$12M-7.7%

Rosuzet

$6M+50.0%

Jada

$5M-66.7%

Ontruzant

$5M-72.2%

Similar metrics at other companies

BIIBVUMERITY — Total Revenue

$179M+29.0%

UTHRTotal Tyvaso — Total revenues

$457.5M-1.9%

BMRNTotal Revenue

$766.21M+2.8%

JAZZTotal Revenue

$1.07B+19.1%

GILDBiktarvy — Total revenues

$3.36B+6.7%

TVTXTotal net product sales — Total Revenue

$124.49M+64.1%

Other financials

Income statement

See full

Revenue$1.5B-3.5%

Gross profit$783.0M-6.9%

Net income$146.0M+67.8%

EPS (diluted)$0.55+66.7%

Balance sheet

See full

Cash & equivalents$1.1B+104%

Total debt$8.6B-4.3%

Total equity$903.0M+66.6%

Total assets$13.0B-1.2%

Cash flow

See full

Operating cash flow$225.0M+200%

CapEx$37.0M+15.6%

Free cash flow$188.0M+337%

Valuation

See full

Market cap$3.53B-59.4%

Profitability

See full

Gross margin52.8%-4.4pp

Net margin8%-12.3pp

FCF margin11.1%-1.3pp

Returns & leverage

See full

Return on equity71.6%—

Debt / equity9.5×-7.0×

Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's vtama — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Organon's vtama — revenue?: Organon (OGN) reported vtama — revenue of $25M in Q1 2026.
How has Organon's vtama — revenue changed year-over-year?: Organon's vtama — revenue increased by 4.2% year-over-year, from $24M to $25M.
What does vtama — revenue mean?: This metric represents the total gross sales generated from the specific pharmaceutical product or therapeutic line. It serves as a primary indicator of market adoption, commercial success, and the revenue-generating capacity of the asset within the company's portfolio.